PMID- 29915655
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2000-9666 (Print)
IS  - 2000-9666 (Electronic)
IS  - 2000-9666 (Linking)
VI  - 8
IP  - 3
DP  - 2018
TI  - To be or not to be a case of heparin resistance.
PG  - 145-148
LID - 10.1080/20009666.2018.1466599 [doi]
AB  - Heparin resistance can be defined as high doses of unfractionated heparin (UFH), 
      greater than 35,000 IU/day, required to raise the activated partial 
      thromboplastin time (aPTT) and activated coagulation time (ACT) to within 
      therapeutically desired ranges or the impossibility of doing so. The most common 
      pathology responsible is the deficiency of anti-thrombin III (ATIII) deficiency. 
      Other clinically relevant conditions that can present with heparin resistance are 
      congenital deficiencies; use of high doses of heparin during extracorporeal 
      circulation, use of asparaginase therapy and disseminated intravascular 
      coagulation (DIC). Most of these conditions effect the ATIII levels. Patients are 
      typically identified in an acute phase, when determination of the cause of 
      resistance is challenging. We present a case where a patient presented with 
      suspected heparin resistance in an acute phase of sickness, where timely 
      intervention was able to prevent a potentially fatal situation. Abbreviations: 
      Neuroendocrine tumors (NETs), World health Organization (WHO), Radiation therapy 
      (RT).
FAU - Durrani, Jibran
AU  - Durrani J
AD  - Temple University Hospital affiliate, Philadelphia, PA, USA.
FAU - Malik, Faizan
AU  - Malik F
AD  - Temple University Hospital affiliate, Philadelphia, PA, USA.
FAU - Ali, Naveed
AU  - Ali N
AD  - Temple University Hospital affiliate, Philadelphia, PA, USA.
FAU - Jafri, Syed Imran Mustafa
AU  - Jafri SIM
AD  - Temple University Hospital affiliate, Philadelphia, PA, USA.
LA  - eng
PT  - Case Reports
DEP - 20180612
PL  - United States
TA  - J Community Hosp Intern Med Perspect
JT  - Journal of community hospital internal medicine perspectives
JID - 101601396
PMC - PMC5998275
OTO - NOTNLM
OT  - Activated partial thromboplastin time (aPTT)
OT  - activated coagulation time (ACT)
OT  - anti-factor 10a (AF 10a)
OT  - anti-thrombin III (ATIII)
OT  - disseminated intravascular coagulation (DIC)
OT  - low molecular weight heparin(LMWH)
OT  - pulmonary embolism (PE)
OT  - unfractionated heparin(UFH)
EDAT- 2018/06/20 06:00
MHDA- 2018/06/20 06:01
PMCR- 2018/06/12
CRDT- 2018/06/20 06:00
PHST- 2018/01/17 00:00 [received]
PHST- 2018/04/12 00:00 [accepted]
PHST- 2018/06/20 06:00 [entrez]
PHST- 2018/06/20 06:00 [pubmed]
PHST- 2018/06/20 06:01 [medline]
PHST- 2018/06/12 00:00 [pmc-release]
AID - 1466599 [pii]
AID - 10.1080/20009666.2018.1466599 [doi]
PST - epublish
SO  - J Community Hosp Intern Med Perspect. 2018 Jun 12;8(3):145-148. doi: 
      10.1080/20009666.2018.1466599. eCollection 2018.